Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin

Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin

Abstract Cell surface mesothelin (MSLN) can be solubilized and released into the systemic circulation. The resulting soluble MSLN (sMSLN) may interfere with therapies targeting surface MSLN. We investigated the effects of sMSLN on anetumab, an antibody-based therapy against MSLN, anetumab ravtansine...

Full description

Saved in:
Bibliographic Details
Main Authors: Katherine E. R. Smith, Jennifer R. Ayers-Ringler, Jacob J. Orme, Fabrice Lucien, Yohan Kim, Jeffrey L. Winters, Aaron S. Mansfield
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Soluble mesothelin
Mesothelioma
Soluble oncogenic proteins
Therapeutic plasma exchange
Protease inhibitors
Online Access:https://doi.org/10.1038/s41598-025-97952-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-97952-x

Similar Items